Noninvasive FFR Measurements for Coronary Interventions
CathWorks is a medical technology company focused on applying its advanced computational science platform to optimize coronary artery disease (CAD) therapy decisions and elevate coronary angiography from visual assessment to an objective, FFR-based decision-making tool for physicians. The companys current focus is specifically on bringing the CathWorks FFRangio System to market in order to provide quick, precise, and objective intraprocedural FFR guidance that will be practical for every case. CathWorks FFRangio System carries the CE mark and received FDA 510(k) clearance in December 2018.
| Name | CathWorks |
|---|---|
| Slug | cathworks |
| Type / kind | startup |
| Crunchbase ID | cathworks |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwMTErogKDA |
| Status | acquired |
|---|---|
| Status reason | Acquired by Medtronic on Feb 2026 |
| Last update | 2026-05-17 |
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Kefar Sava |
| HQ address | Rapaport Street 3, Kfar Saba, Israel |
| Website | https://cath.works |
|---|---|
| Careers page | https://cath.works/careers |
| https://www.linkedin.com/company/29011590 | |
| Twitter / X | https://twitter.com/CathWorks |
| https://www.facebook.com/CathWorksFFRangio | |
| YouTube | https://www.youtube.com/channel/UCGZgKKYj3BUqgCRadZv7Fmw |
| Total raised | $151.8M |
|---|---|
| Current stage | Acquired |
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}